Serologic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Infection Among Hospital Health Care Workers.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 07 2021
Historique:
entrez: 28 7 2021
pubmed: 29 7 2021
medline: 13 8 2021
Statut: epublish

Résumé

It is unclear when, where, and by whom health care workers (HCWs) working in hospitals are infected with SARS-CoV-2. To determine how often and in what manner nosocomial SARS-CoV-2 infection occurs in HCW groups with varying exposure to patients with COVID-19. This cohort study comprised 4 weekly measurements of SARS-CoV-2-specific antibodies and collection of questionnaires from March 23 to June 25, 2020, combined with phylogenetic and epidemiologic transmission analyses at 2 university hospitals in the Netherlands. Included individuals were HCWs working in patient care for those with COVID-19, HCWs working in patient care for those without COVID-19, and HCWs not working in patient care. Data were analyzed from August through December 2020. Varying work-related exposure to patients infected with SARS-CoV-2. The cumulative incidence of and time to SARS-CoV-2 infection, defined as the presence of SARS-CoV-2-specific antibodies in blood samples, were measured. Among 801 HCWs, there were 439 HCWs working in patient care for those with COVID-19, 164 HCWs working in patient care for those without COVID-19, and 198 HCWs not working in patient care. There were 580 (72.4%) women, and the median (interquartile range) age was 36 (29-50) years. The incidence of SARS-CoV-2 was increased among HCWs working in patient care for those with COVID-19 (54 HCWs [13.2%; 95% CI, 9.9%-16.4%]) compared with HCWs working in patient care for those without COVID-19 (11 HCWs [6.7%; 95% CI, 2.8%-10.5%]; hazard ratio [HR], 2.25; 95% CI, 1.17-4.30) and HCWs not working in patient care (7 HCWs [3.6%; 95% CI, 0.9%-6.1%]; HR, 3.92; 95% CI, 1.79-8.62). Among HCWs caring for patients with COVID-19, SARS-CoV-2 cumulative incidence was increased among HCWs working on COVID-19 wards (32 of 134 HCWs [25.7%; 95% CI, 17.6%-33.1%]) compared with HCWs working on intensive care units (13 of 186 HCWs [7.1%; 95% CI, 3.3%-10.7%]; HR, 3.64; 95% CI, 1.91-6.94), and HCWs working in emergency departments (7 of 102 HCWs [8.0%; 95% CI, 2.5%-13.1%]; HR, 3.29; 95% CI, 1.52-7.14). Epidemiologic data combined with phylogenetic analyses on COVID-19 wards identified 3 potential HCW-to-HCW transmission clusters. No patient-to-HCW transmission clusters could be identified in transmission analyses. This study found that HCWs working on COVID-19 wards were at increased risk for nosocomial SARS-CoV-2 infection with an important role for HCW-to-HCW transmission. These findings suggest that infection among HCWs deserves more consideration in infection prevention practice.

Identifiants

pubmed: 34319354
pii: 2782430
doi: 10.1001/jamanetworkopen.2021.18554
pmc: PMC9437910
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2118554

Références

Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Virus Evol. 2018 Jun 08;4(1):vey016
pubmed: 29942656
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Nat Commun. 2020 Dec 11;11(1):6351
pubmed: 33311501
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Occup Environ Med. 2020 Dec 9;:
pubmed: 33298533
Nat Commun. 2020 Nov 12;11(1):5744
pubmed: 33184284
Anaesth Crit Care Pain Med. 2020 Oct;39(5):595-596
pubmed: 32861816
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
JAMA. 2020 Aug 4;324(5):441-442
pubmed: 32749495
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Antimicrob Resist Infect Control. 2021 Jan 6;10(1):7
pubmed: 33407833
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
Elife. 2020 Aug 21;9:
pubmed: 32820721
Cochrane Database Syst Rev. 2020 May 15;5:CD011621
pubmed: 32412096
J Hosp Infect. 2021 Feb;108:120-134
pubmed: 33212126
BMJ. 2020 Oct 28;371:m3582
pubmed: 33115726
Virus Evol. 2019 Oct 09;5(2):vez039
pubmed: 31616568
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
Am J Clin Pathol. 2020 Oct 13;154(5):592-595
pubmed: 32914176
J Hosp Infect. 2013 Nov;85(3):170-82
pubmed: 24051190
Lancet Infect Dis. 2021 Jan;21(1):23-24
pubmed: 32437699

Auteurs

Jonne J Sikkens (JJ)

Department of Internal Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

David T P Buis (DTP)

Department of Internal Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Edgar J G Peters (EJG)

Section Infectious Diseases, Department of Internal Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Mireille Dekker (M)

Department of Medical Microbiology and Infection Prevention, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Michiel Schinkel (M)

Center for Experimental Molecular Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Tom D Y Reijnders (TDY)

Center for Experimental Molecular Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Alex R Schuurman (AR)

Center for Experimental Molecular Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Justin de Brabander (J)

Center for Experimental Molecular Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

A H Ayesha Lavell (AHA)

Department of Internal Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Jaap J Maas (JJ)

Department of Occupational Health and Safety, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Jelle Koopsen (J)

Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Alvin X Han (AX)

Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Colin A Russell (CA)

Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Janke Schinkel (J)

Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Marcel Jonges (M)

Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Sébastien Matamoros (S)

Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Suzanne Jurriaans (S)

Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Rosa van Mansfeld (R)

Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

W Joost Wiersinga (WJ)

Division of Infectious Diseases, Department of Internal Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Yvo M Smulders (YM)

Department of Internal Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Menno D de Jong (MD)

Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Marije K Bomers (MK)

Section Infectious Diseases, Department of Internal Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH